CPIG
PHAT icon

Chicago Partners Investment Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Chicago Partners Investment Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,266
Closed -$206K – 554
2021
Q1 		$206K Buy
+5,266
New +$220K 0.02% 484

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Chicago Partners Investment Group's PHAT Position: Q2 2021 in Review

Chicago Partners Investment Group sold out of Phathom Pharmaceuticals (PHAT) in Q2 2021, closing a stake of 5,266 shares — an estimated $206K sold.

Chicago Partners Investment Group first reported a position in PHAT in Q1 2021 and held it in 1 quarter. The position peaked at $206K in Q1 2021. 79 funds tracked by Wall St. Rank hold PHAT as of Q2 2021.

  • Chicago Partners Investment Group reported no remaining Phathom Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Chicago Partners Investment Group sold 5,266 Phathom Pharmaceuticals shares in Q2 2021, an estimated $206K.
  • Chicago Partners Investment Group first reported a position in Phathom Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Chicago Partners Investment Group's Phathom Pharmaceuticals position peaked at $206K in Q1 2021.
  • 79 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2021.

Based on Chicago Partners Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.